https://www.selleckchem.com/products/g007-lk.html
The study aimed to investigate the effectiveness and tolerance of biological disease-modifying antirheumatic drugs (bDMARDs) therapy administered concomitantly with tacrolimus (TAC) treatment in patients with rheumatoid arthritis. 2792 patients who underwent therapy with five bDMARDs (etanercept ETN, adalimumab ADA, golimumab GLM, tocilizumab TCZ, and abatacept ABT) were enrolled. Among the study subjects, 1582 were concomitant methotrexate (MTX group), 147 were concomitant TAC (TAC group), and 1063 were non-concomitant MTX and TAC (non
Curtir
Comentario
Compartilhar
